Clinical trials · source year
77 selected, source-linked clinical trial records dated 2025. This is selective source coverage, not a complete timeline.
77 selected records.
14 connected profiles.
77 distinct public records.
Cited chronology
Plecanatide
PeptideScanner retained ClinicalTrials.gov record NCT03596905 at 2026-07-30T18:18:33.534Z. Its registry update date was 2025-12-31, and PeptideScanner's reviewed identity mapping was plecanatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03809000 at 2026-07-30T18:18:33.523Z. Its registry update date was 2025-12-30, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT06921824 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT07300982 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-24, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT07262957 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Maridebart cafraglutide
PeptideScanner retained ClinicalTrials.gov record NCT06987695 at 2026-07-30T18:18:33.507Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT07029009 at 2026-07-30T18:18:33.514Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00001481 at 2026-07-30T18:18:33.509Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT05189457 at 2026-07-30T18:18:33.510Z. Its registry update date was 2025-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01225055 at 2026-07-30T18:18:33.512Z. Its registry update date was 2025-12-02, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Lixisenatide
PeptideScanner retained ClinicalTrials.gov record NCT03439943 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-28, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02023463 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT07242612 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-21, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tesamorelin
PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Elamipretide
PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00262470 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-08, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT06872060 at 2026-07-30T18:20:54.427Z. Its registry update date was 2025-10-03, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT06348264 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-23, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT03000946 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03678025 at 2026-07-30T18:22:04.918Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT06193616 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-05, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03298087 at 2026-07-30T18:23:09.823Z. Its registry update date was 2025-08-01, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT03241706 at 2026-07-30T18:24:37.180Z. Its registry update date was 2025-07-25, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Vosoritide
PeptideScanner retained ClinicalTrials.gov record NCT07073014 at 2026-07-30T18:24:37.179Z. Its registry update date was 2025-07-18, and PeptideScanner's reviewed identity mapping was vosoritide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT02078726 at 2026-07-30T18:24:37.187Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02903368 at 2026-07-30T18:26:04.260Z. Its registry update date was 2025-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06745128 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT07018544 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06073184 at 2026-07-30T18:26:04.258Z. Its registry update date was 2025-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT03651765 at 2026-07-30T18:27:14.161Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT06974344 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-15, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06937060 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT02278185 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-11, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT03289741 at 2026-07-30T18:27:14.159Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06959784 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-07, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04889183 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Tirzepatide
PeptideScanner retained ClinicalTrials.gov record NCT06918405 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-09, and PeptideScanner's reviewed identity mapping was tirzepatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT05520775 at 2026-07-30T18:29:04.228Z. Its registry update date was 2025-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00687739 at 2026-07-30T18:29:04.227Z. Its registry update date was 2025-04-01, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT02457156 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT04873050 at 2026-07-30T18:30:10.991Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03158805 at 2026-07-30T18:30:10.979Z. Its registry update date was 2025-03-12, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00463983 at 2026-07-30T18:30:10.977Z. Its registry update date was 2025-03-05, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT04881110 at 2026-07-30T18:30:10.981Z. Its registry update date was 2025-03-03, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT03944434 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Setmelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04725240 at 2026-07-30T18:31:14.558Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was setmelanotide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT03133195 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-15, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT06764056 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗